Histocell — No stage disclosed · €0.4M

Histocell issued new shares to Japanese stem-cell company ReproCELL Inc. for €0.4M, announced on 7 November 2022 with funding expected 8 November and closing 22 November 2022; ReproCELL was already an indirect shareholder via the Cell Innovation Partners fund and made this direct investment to strengthen its clinical iPSC manufacturing capacity in Europe. No venture stage was disclosed, so the round is classified as Other.